Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Klapa

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Antioxidants (Basel, Switzerland)|April 28, 2023
Analysis of Single- and Double-Stranded DNA Damage in Osteoblastic Cells after Hyperbaric Oxygen ExposureNele Schönrock, Frauke Tillmans, Susanne Sebens, et al.
Clinical and Experimental Rheumatology|April 24, 2010
Lower numbers of FoxP3 and CCR4 co-expressing cells in an elevated subpopulation of CD4+CD25high regulatory T cells from Wegener's granulomatosisSebastian Klapa, Antje Mueller, Elena Csernok, et al.
International Journal of Molecular Sciences|July 2, 2021
Granulomatous Inflammation in ANCA-Associated VasculitisAntje Müller, Bettina Krause, Anja Kerstein-Stähle, et al.
Clinical and Experimental Rheumatology|September 18, 2025
Avacopan with combined cyclophosphamide and rituximab for induction therapy in severe ANCA-associated vasculitis: retrospective observational study of 30 patients in two German referral centresGunter Assmann, El-Baraa Adjailia, Sebastian Klapa, et al.
Clinical and Experimental Rheumatology|September 2, 2025
Real-world outcomes of rituximab- and cyclophosphamide-based induction therapy regimens alone and in combination over 24 months in ANCA-associated vasculitisKatja von Allwörden, Sebastian Klapa, Stephan Christian Werth, et al.
The Lancet. Rheumatology|April 4, 2024
Myeloperoxidase-specific antineutrophil cytoplasmic antibody-associated vasculitisSabrina Arnold, A Richard Kitching, Veronique Witko-Sarsat, et al.
Journal of Autoimmunity|January 2, 2017
Environmental factor and inflammation-driven alteration of the total peripheral T-cell compartment in granulomatosis with polyangiitisAnja Kerstein, Silke Schüler, Otávio Cabral-Marques, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 21, 2022
Low Concentrations of C5a Complement Receptor Antibodies Are Linked to Disease Activity and Relapse in Antineutrophil Cytoplasmic Autoantibody-Associated VasculitisSebastian Klapa, Antje Müller, Andreas Koch, et al.
Frontiers in Immunology|May 1, 2026
ANCA-associated vasculitis is associated with an increased risk of cardiac and vascular morbidity: results of a large-scale propensity-matched global retrospective cohort studySebastian Klapa, Katja Bieber, Artem Vorobyev, et al.
The Lancet. Rheumatology|March 31, 2025
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort studyAnna Kernder, Tim Filla, Rhea Friedrich, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Antioxidants (Basel, Switzerland)|April 28, 2023
Analysis of Single- and Double-Stranded DNA Damage in Osteoblastic Cells after Hyperbaric Oxygen ExposureNele Schönrock, Frauke Tillmans, Susanne Sebens, et al.
Clinical and Experimental Rheumatology|April 24, 2010
Lower numbers of FoxP3 and CCR4 co-expressing cells in an elevated subpopulation of CD4+CD25high regulatory T cells from Wegener's granulomatosisSebastian Klapa, Antje Mueller, Elena Csernok, et al.
International Journal of Molecular Sciences|July 2, 2021
Granulomatous Inflammation in ANCA-Associated VasculitisAntje Müller, Bettina Krause, Anja Kerstein-Stähle, et al.
Clinical and Experimental Rheumatology|September 18, 2025
Avacopan with combined cyclophosphamide and rituximab for induction therapy in severe ANCA-associated vasculitis: retrospective observational study of 30 patients in two German referral centresGunter Assmann, El-Baraa Adjailia, Sebastian Klapa, et al.
Clinical and Experimental Rheumatology|September 2, 2025
Real-world outcomes of rituximab- and cyclophosphamide-based induction therapy regimens alone and in combination over 24 months in ANCA-associated vasculitisKatja von Allwörden, Sebastian Klapa, Stephan Christian Werth, et al.
The Lancet. Rheumatology|April 4, 2024
Myeloperoxidase-specific antineutrophil cytoplasmic antibody-associated vasculitisSabrina Arnold, A Richard Kitching, Veronique Witko-Sarsat, et al.
Journal of Autoimmunity|January 2, 2017
Environmental factor and inflammation-driven alteration of the total peripheral T-cell compartment in granulomatosis with polyangiitisAnja Kerstein, Silke Schüler, Otávio Cabral-Marques, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 21, 2022
Low Concentrations of C5a Complement Receptor Antibodies Are Linked to Disease Activity and Relapse in Antineutrophil Cytoplasmic Autoantibody-Associated VasculitisSebastian Klapa, Antje Müller, Andreas Koch, et al.
Frontiers in Immunology|May 1, 2026
ANCA-associated vasculitis is associated with an increased risk of cardiac and vascular morbidity: results of a large-scale propensity-matched global retrospective cohort studySebastian Klapa, Katja Bieber, Artem Vorobyev, et al.
The Lancet. Rheumatology|March 31, 2025
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort studyAnna Kernder, Tim Filla, Rhea Friedrich, et al.
Pageof 3